Display Settings:

Format
Sort by

Send to:

Choose Destination

Results: 5

1.

Tumor response and toxicity of neoadjuvant erlotinib in patients with early-stage non-small-cell lung cancer.

Schaake EE, Kappers I, Codrington HE, Valdés Olmos RA, Teertstra HJ, van Pel R, Burgers JA, van Tinteren H, Klomp HM.

J Clin Oncol. 2012 Aug 1;30(22):2731-8. doi: 10.1200/JCO.2011.39.4882. Epub 2012 Jul 2.

PMID:
22753915
[PubMed - indexed for MEDLINE]
Free Article
2.

Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.

Murphy M, Stordal B.

Drug Resist Updat. 2011 Jun;14(3):177-90. doi: 10.1016/j.drup.2011.02.004. Epub 2011 Mar 24. Review.

PMID:
21435938
[PubMed - indexed for MEDLINE]
3.

Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer.

Smith J.

Clin Ther. 2005 Oct;27(10):1513-34. Review.

PMID:
16330289
[PubMed - indexed for MEDLINE]
4.

[Adverse effects of new biological therapies for non-small-cell bronchial cancer].

Castel M, Pathak A, Despas F, Mazières J.

Presse Med. 2011 Apr;40(4 Pt 1):415-9. doi: 10.1016/j.lpm.2011.02.004. Epub 2011 Mar 9. Review. French.

PMID:
21392933
[PubMed - indexed for MEDLINE]
5.

Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint.

Hellmann MD, Chaft JE, William WN Jr, Rusch V, Pisters KM, Kalhor N, Pataer A, Travis WD, Swisher SG, Kris MG; University of Texas MD Anderson Lung Cancer Collaborative Group.

Lancet Oncol. 2014 Jan;15(1):e42-50. doi: 10.1016/S1470-2045(13)70334-6. Review.

PMID:
24384493
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk